Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics BNR

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Burning Rock Biotech Ltd

BNR
Current price
4.22 USD +0.3 USD (+7.57%)
Last closed 3.98 USD
ISIN US12233L1070
Sector Healthcare
Industry Diagnostics & Research
Exchange NASDAQ
Capitalization 44 151 336 USD
Yield for 12 month -41.43 %
1Y
3Y
5Y
10Y
15Y
BNR
21.11.2021 - 28.11.2021

Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS) based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various cancer types, including pan-cancer, lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, and ovarian cancer. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples, and OncoCompass, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore, which assesses microsatellite loci related to MSI status and detects mutations in genes associated with gastrointestinal cancers. It also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of the key products. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China. Address: No. 5, Xingdao Ring Road North, Guangzhou, China, 510005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.03 USD

P/E Ratio

Dividend Yield

Financials BNR

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+71 973 824 USD

Last Year

+74 989 535 USD

Current Quarter

+18 569 236 USD

Last Quarter

+17 584 138 USD

Current Year

+50 566 501 USD

Last Year

+50 681 894 USD

Current Quarter

+13 590 584 USD

Last Quarter

+12 477 256 USD
EBITDA -180 412 256 USD
Operating Margin TTM -11.41 %
Price to Earnings
Return On Assets TTM -14.39 %
PEG Ratio
Return On Equity TTM -37.03 %
Wall Street Target Price 4.03 USD
Revenue TTM 523 280 992 USD
Book Value 53.13 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 5.90 %
Dividend Yield
Gross Profit TTM 374 107 008 USD
Earnings per share -3.22 USD
Diluted Eps TTM -3.22 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -45.59 %

Stock Valuation BNR

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.029
Price Sales TTM 0.084
Enterprise Value EBITDA -0.17
Price Book MRQ 0.52

Technical Indicators BNR

For 52 Weeks

2.18 USD 7.90 USD
50 Day MA 3.11 USD
Shares Short Prior Month 41 457
200 Day MA 4.56 USD
Short Ratio 0.91
Shares Short 40 443
Short Percent 0.56 %